Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

22-06-2021 | ASCO 2021 | Conference coverage | Video

Lung cancer: Clinical insights into key research

Gilberto Lopes shares his lung cancer highlights from the 2021 ASCO Annual Meeting, including the IMpower010 trial, the MYLUNG study of real-world molecular testing, and updates on the CodeBreaK 100 and CHRYSALIS studies (8:06).

00:00 - Introduction
00:30 - MYLUNG study
02:44 - CodeBreaK 100 trial
03:52 - CHRYSALIS trial
04:48 - IMpower010 trial

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

04-06-2021 | ASCO 2021 | Conference coverage | News

Adjuvant atezolizumab delays recurrence in early-stage NSCLC patients

05-06-2021 | ASCO 2021 | Conference coverage | Video

Sotorasib continues to show potential in KRAS-mutant NSCLC

15-06-2021 | ASCO 2021 | Conference coverage | Video

IMpower010 supports adjuvant atezolizumab in early-stage NSCLC
Image Credits